Liraglutide is a GLP-1 (glucagon-like peptide 1) agonist
Depending on the final federal register language, additional peptides from the 2023 restricted list such as Selank, Semax, or KPV may also fall within scope
Through its modulation of the NNMT-SAM-NAD+ axis, it enhances energy expenditure and supports more efficient utilization of fat stores for energy, making it a strong candidate in studies exploring metabolic optimization and obesity control
[DOI] [PubMed] [Google Scholar] 85.Pollack A
If you are considering B12 injections for general wellness rather than for a diagnosed deficiency, our experienced providers will discuss your individual goals, symptoms, and lab results to determine if supplementation is appropriate for you
Semaglutide activates GLP-1 receptors in the pancreas, gut, and hypothalamus to reduce appetite, slow gastric emptying, and improve glycemic control